Tom Powles

This year’s Uromigos Cup is America 🇺🇸 🇨🇦 vs Eurasia 🇯🇵 🇨🇳 🇦🇺 🇪🇺 . Eurasia is already 1-0 ahead after winning the darts 🎯 at the Uromigos party. Here @montypal starts to pick his americas team in this multidisciplinary and wide ranging competition. It will finish at the…

#KCRS25 En RCC, VEGF/HIF y PD1/CTLA4 han mejorado resultados en 1-2L. Faltan datos en combos con nuevos HIF (casdatifan), bmk (KIM1/PDL1). Tripletes y TIGIT/LAG3 no han mostrado beneficio claro. RAMPART (durva/durva+trem vs obs) cierra era IO adyuvante. @OncoAlert @Uromigos

#KCRS25 @AlbigesL KNB67 (nccRCC) : Pembro+lenva muestra eficacia sostenida a 3 años en 1L 📌ORR 51% (10% RC) 📌DOR 23.5m (35% >36m) 📌SG 41.5m, PFS 17.9m 👉🏻Actividad en papilar/cromófobo @OncoAlert @Uromigos @kidneycan

Longer follow up for Enfortumab Vedotin & Pembro in urothelial cancer @Annals_Oncology shows mOS at nearly 3 yrs (34 mnths) with 50% of responses (68%) continuing at 2 years! Experience in tox management is important. Duration of therapy uncertain in CR gbr01.safelinks.protection.outlook.com/?url=https%3A%…

The RAMPART trial is the last R3 adjuvant ICI trial in RCC. Durva vs durva/tremi vs observation. Inconsistent ICI data previously in this space, but we’ve never seen a positive OS result for a PD-L1 trial in RCC. It also has the 1st non clear cell pts #KCRS25

1st and 2nd line therapy #KCRS25 . VEGF/HIF and PD1/CTLA4 together or sequenced have largely been explored from adjuvant to 2nd, improving outcomes. Unexplored areas include HIF combos, new HIF (casdatifan), KIM1/PDL1 biomarkers. Triplet therapy & TIGIT/LAG3 etc have struggled.

I think just further evidence that we really don’t know how to sequence these therapies…

Hidden gem 💎 💎 #KCRS25 The CONTACT3 trial showed sequencing PD1 and PDL1 therapy was not benificisl in renal cancer. @BradMcG04 explores whether 2nd line Cabozantinib is more active after prior ipi/nivo or VEGF/PD1 with surprising results @OncoAlert @DrChoueiri @montypal

KIM1 is the most promising biomarker in RCC but how do we incorporate it into clinical practice? #KCRS25 @VincentWenxinXu We need to agree on what is high + randomised trials needed. It feels a distance away. Low levels may spare some adjuvant pembro but prospect testing needed.

We need to randomise in papillary RCC #KCRS25 @montypal .Single arm trials can be misleading. ⏩️ Stellar304 (Zanza+nivo vs sun) & SAMETA (Savo+durva vs sun). Global access to VEGF/PD1 combos is limited due to weak single arm data. To change global practice we need to randomise

Just three days until KCRS 2025! We’re getting ready to welcome researchers, clinicians, advocates, and patients from around the world to explore the future of #KidneyCancer research. #KCRS25 #AcceleratingCures

🏃El ejercicio estructurado postQT en ca colon estadio II/III demuestra beneficio en SLE (HR 0.72): 📌SLE 5 años: 74% vs 80% 📌Por cada 16 pacientes, se evitó 1 recaída o nuevo tumor. 🎙️Entrevista al Prof Christopher Booth: open.spotify.com/episode/0CNTpN… @OncoAlert @Uromigos

🚨 Aprobado en 🇪🇺: durvalumab (Imfinzi) como IO perioperatoria para #MIBC. Ensayo NIAGARA fase III: 📌 -32% riesgo recaída o muerte (HR 0.68) 📌 EFS NR vs 46m @OncoAlert astrazeneca.com/media-centre/p…

🔗 @Annals_Oncology ¿Qué se necesita para lograr ensayos neoadyuvantes que cambien la práctica en ca renal? Estudio Delphi del consorcio INKCC: 📌96% pide estrategia clara. 📌87% apoyó ensayos adaptativos 📌78% cree prematuro un fase 3 annalsofoncology.org/article/S0923-… @OncoAlert

Thanks for advertising @APCCC_Lugano and do not forget that registration is now open for 2026 on apccc.org for everyone interested. And we will for the first time also accept abstracts! Stay tuned for other news!

Thanks @tompowles1 @brian_rini @Uromigos for this wonderful podcast discussing structured exercise program benefits in resected CRC in the CHALLENGE trial! Love the fun discussion on running & how Chris Booth & team turned this idea into reality. Kudos to the study team on…

Another good reason to go for a run podcasts.apple.com/gb/podcast/the…

The 4th live Uromigos meeting is happening on 7th & 8th Nov ‘25 in Nashville. It’s going to have an international flavour with America’s 🇺🇸 🇨🇦 vs Eurasia 🇯🇵 🇨🇳 🇮🇳 🇦🇺 🇪🇺 Uromigos Cup competition (details to follow). Sessions ranging from ADCs in MIBC to the changing shape of…

Gem/cis/durvalumab is approved in the EU for muscle invasive bladder cancer (NIAGARA study). It’s the only immune therapy study in the adjuvant or neoadjuvant setting with significant OS. ⬆️ pCR and EFS support this appr @OncoAlert @Annals_Oncology astrazeneca.com/media-centre/p…

Great News in #BladderCancer Kudos to @tompowles1 & the Patients and Investigators involved in NIAGARA ‼️